title: Bevacizumab in vitreous haemorrhage secondary to radiation retinopathy.
abstract: Radiation retinopathy is a delayed-onset side effect of radiation exposure caused by retinal ischaemia that may induce proliferative retinopathy with neovascularisation, vitreous haemorrhage and macular oedema. An otherwise healthy, 51-year-old male patient who had been diagnosed with olfactory neuroblastoma and undergone complete surgical removal of the lesion followed by cranial irradiation developed bilateral cataracts and radiation retinopathy. The patient was treated by panretinal photocoagulation (PRP), followed by three-port pars-plana vitrectomy. Recurrent episodes of vitreous haemorrhages occurred following surgery and the patient was successfully treated by one intravitreal injection of bevacizumab with resolution of vitreous blood. Vitreous haemorrhage recurred 6 months later and a scheduled treatment with intravitreal bevacizumab every 4 months was established, preventing further haemorrhagic episodes. Six months after the last injection, a new episode of vitreous haemorrhage occurred. Scheduled intravitreal bevacizumab injections may help prevent recurrent vitreous haemorrhages in vitrectomised patients with radiation retinopathy.
authors: Department of Ophthalmology, Pio del Rio Hortega University Hospital, Valladolid, Spain.
authors: Javier Antonio
authors: JA
authors: Montero
authors: Giovanni
authors: G
authors: Yanez-Castro
authors: Maria Eugenia
authors: ME
authors: Sanchis-Merino
authors: Jose Maria
authors: JM
authors: Ruiz-Moreno
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011832:Radiation Injuries / Q000150:complications / Q000209:etiology* / Q000473:pathology; D012164:Retinal Diseases / Q000209:etiology* / Q000473:pathology; D014823:Vitreous Hemorrhage / Q000188:drug therapy / Q000209:etiology*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab